NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $18.73 -0.28 (-1.45%) As of 12:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Viridian Therapeutics Stock (NASDAQ:VRDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$18.27▼$19.1350-Day Range$18.92▼$24.8052-Week Range$13.18▼$34.29Volume603,589 shsAverage Volume2.09 million shsMarket Capitalization$2.12 billionP/E RatioN/ADividend YieldN/APrice Target$38.69Consensus RatingModerate Buy Company Overview Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biotechnology company focused on developing treatments for autoimmune and inflammatory diseases. The company’s primary research centers on antibody-based medicines designed to target the insulin-like growth factor 1 receptor (IGF-1R), a biological pathway associated with thyroid eye disease (TED). Viridian’s pipeline includes veligrotug, an investigational monoclonal antibody being developed for TED, as well as additional drug candidates intended to provide alternative dosing options and potentially address broader autoimmune conditions. The company has also explored subcutaneous formulations and longer-acting approaches designed to improve the convenience of treatment. Its candidates remain subject to clinical testing and regulatory review, and the company does not currently have a broadly marketed commercial product. Founded in 2018, Viridian is headquartered in Waltham, Massachusetts. The company’s activities have focused on research, clinical development and regulatory advancement in the United States and other international markets through global clinical programs. Viridian is led by Chief Executive Officer Bill Lis.AI Generated. May Contain Errors. Read More Viridian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 410th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialViridian Therapeutics has a consensus price target of $38.69, representing about 106.0% upside from its current price of $18.79.Amount of Analyst CoverageViridian Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.60% of the float of Viridian Therapeutics has been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 15.74, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 0.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.56 News SentimentViridian Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,194.00 in company stock.Percentage Held by Insiders2.40% of the stock of Viridian Therapeutics is held by insiders.Percentage Held by InstitutionsViridian Therapeutics has minimal institutional ownership at this time.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRDN Stock News HeadlinesEmergent Biosolutions (NYSE:EBS) and Viridian Therapeutics (NASDAQ:VRDN) Head to Head ContrastOctober 4 at 3:45 AM | americanbankingnews.comWall Street Zen Downgrades Viridian Therapeutics (NASDAQ:VRDN) to Strong SellOctober 4 at 1:07 AM | americanbankingnews.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 6 at 1:00 AM | American Hartford Gold (Ad)Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 30, 2026 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Upgraded to Sell at Wall Street ZenSeptember 26, 2026 | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)September 23, 2026 | theglobeandmail.comViridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC SaysSeptember 22, 2026 | finance.yahoo.comViridian Therapeutics: Two Products, One Commercial BuildoutSeptember 17, 2026 | seekingalpha.comSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $31.12 at the start of the year. Since then, VRDN shares have decreased by 39.6% and is now trading at $18.7860. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by $0.02. The business earned $0.28 million during the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 72.97% and a negative net margin of 505.86%. When did Viridian Therapeutics IPO? Viridian Therapeutics (VRDN) raised $9 million in an initial public offering on Thursday, June 12th 2014. The company issued 850,000 shares at a price of $10.00-$12.00 per share. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2026Today10/06/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VRDN's financial health is in the Green zone, according to TradeSmith. VRDN has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRDN CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees252Year FoundedN/APrice Target and Rating Average Price Target for Viridian Therapeutics$38.69 High Price Target$61.00 Low Price Target$22.00 Potential Upside/Downside+105.6%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$342.60 million Net Margins-505.86% Pretax Margin-544.06% Return on Equity-72.97% Return on Assets-42.80% Debt Debt-to-Equity Ratio0.43 Current Ratio16.95 Quick Ratio16.95 Sales & Book Value Annual Sales$71.13 million Price / Sales29.98 Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book3.05Miscellaneous Outstanding Shares113,292,000Free Float110,573,000Market Cap$2.13 billion OptionableOptionable Beta1.11 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:VRDN) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRDN Stock Alerts